Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed refractory chronic lymphoc - Environmental Science - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-08-06 13:19:29		Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc Add to Reading List Source URL: gotoper-com.s3.amazonaws.com Download Document from Source Website File Size: 149,58 KB Share Document on Facebook